An interventional study of B-salicornia in Lacunar Stroke, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
SALACUNAR (LACI-2-polyphenols) is a multi-center randomized controlled trial (RCT) to evaluate the effect of a polyphenol-rich supplement on small vessel neurovascular disease. Specifically, the compound to be tested is a dietary supplement based on Salicornia extract and B vitamins (B-salicornia), which in previous studies has demonstrated a good safety profile and consistent effects in reducing homocysteine levels and improving cognitive outcomes (MOCA) in patients with lacunar infarcts. This has been used to calculate the sample size based on these endpoints. Considering an intragroup variability of the treatment groups (sigma) of 6.07, and accepting an alpha risk of 0.05, a sample of 150 patients per group would achieve a 1-beta statistical power greater than 0.8 in a two-tailed test for differences between means of at least two points on the MOCA scale.
Three hundred patients with lacunar infarcts diagnosed within the last year and confirmed by MRI performed as part of routine clinical practice will be included.
We will administer 500 mg/24 h of the dietary supplement B-Salicornia for six months (or the control group will be managed according to routine clinical practice) following a PROBE design.
Routine blood tests will be performed pre- and post-treatment, with routine vascular parameters such as lipids and homocysteine, as well as baseline and six-month assessments of neuropsychological and gait scales.
21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.
This study's planned enrollment of 300 is above the median of 60 across 15 interventional studies indexed under Stroke, Lacunar.
Browse Stroke, Lacunar studies →Fundación Pública Andaluza para la gestión de la Investigación en Sevilla is the lead sponsor of 120 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patients with lacunar ischemic stroke, confirmed by cranial magnetic resonance imaging performed within the year prior to inclusion, who have an mRS of 3 or less at the time of inclusion will be included (independent patients or those who require assistance with walking). The inclusion age will be between 40 and 90 years.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Food supplement to be taken once a day.
Dietary Supplement: B-salicornia
Without intervention
Dietary supplement based on halophyte plant extracts (experimental) plus regular medical treatment. Dosage: once daily. Duration of study: 6 months.
Six-minute walk test (6MWT)
To evaluate changes in walking performance in patients who took the supplement compared to patients who followed standard clinical practice.
Time frame: 6 months
Neuropsychological questionnaires: Montreal Cognitive Assessment (MOCA)
Assess possible improvements in cognitive function in patients taking the supplement versus patients following standard clinical practice.
Time frame: 6 months
Blood laboratory parameters (homocysteine µmol/L).
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: 6 months
Morisky-Green test count of returned treatment capsules.
Confirm adequate adherence to dietary supplementation.
Time frame: 6 months
Severity of the adverse event.
\- Mild: No antidote or treatment required; brief hospitalisation. - MODERATE: Treatment modification required (e.g., dose change, addition of another drug), but discontinuation of the drug is not essential; prolonged administration of the drug is not essential; prolonged hospitalisation or treatment may be necessary, or specific hospitalisation or treatment may be necessary. - SEVERE: The adverse drug reaction is life-threatening and requires discontinuation of the drug. Drug administration should be discontinued and specific treatment instituted. - FATAL: An adverse drug reaction may directly or indirectly contribute to the death of the patient.
Time frame: 6 months
Blood laboratory parameters (total cholesterol mg/dl).
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: 6 months
Blood laboratory parameters (Low density lipoprotein cholesterol mg/dl).
Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.
Time frame: 6 months
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla →